These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20193683)

  • 1. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response.
    Turner D; Mack D; Leleiko N; Walters TD; Uusoue K; Leach ST; Day AS; Crandall W; Silverberg MS; Markowitz J; Otley AR; Keljo D; Mamula P; Kugathasan S; Hyams J; Griffiths AM
    Gastroenterology; 2010 Jun; 138(7):2282-91. PubMed ID: 20193683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.
    Turner D; Leach ST; Mack D; Uusoue K; McLernon R; Hyams J; Leleiko N; Walters TD; Crandall W; Markowitz J; Otley AR; Griffiths AM; Day AS
    Gut; 2010 Sep; 59(9):1207-12. PubMed ID: 20801771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute ulcerative colitis: the pediatric perspective.
    Turner D
    Dig Dis; 2009; 27(3):322-6. PubMed ID: 19786759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
    Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab.
    Croft A; Walsh A; Doecke J; Cooley R; Howlett M; Radford-Smith G
    Aliment Pharmacol Ther; 2013 Aug; 38(3):294-302. PubMed ID: 23786158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis.
    Cacheux W; Seksik P; Lemann M; Marteau P; Nion-Larmurier I; Afchain P; Daniel F; Beaugerie L; Cosnes J
    Am J Gastroenterol; 2008 Mar; 103(3):637-42. PubMed ID: 18047542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.
    Maser EA; Deconda D; Lichtiger S; Ullman T; Present DH; Kornbluth A
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1112-6. PubMed ID: 18928936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome following infliximab therapy in children with ulcerative colitis.
    Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Stephens M; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Grossman A; Tomer G; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
    Am J Gastroenterol; 2010 Jun; 105(6):1430-6. PubMed ID: 20104217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
    Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
    J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of corticosteroid therapy for ulcerative colitis in children.
    Hyams J; Markowitz J; Lerer T; Griffiths A; Mack D; Bousvaros A; Otley A; Evans J; Pfefferkorn M; Rosh J; Rothbaum R; Kugathasan S; Mezoff A; Wyllie R; Tolia V; delRosario JF; Moyer MS; Oliva-Hemker M; Leleiko N;
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1118-23. PubMed ID: 16820327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.
    Turner D; Otley AR; Mack D; Hyams J; de Bruijne J; Uusoue K; Walters TD; Zachos M; Mamula P; Beaton DE; Steinhart AH; Griffiths AM
    Gastroenterology; 2007 Aug; 133(2):423-32. PubMed ID: 17681163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.
    Lees CW; Heys D; Ho GT; Noble CL; Shand AG; Mowat C; Boulton-Jones R; Williams A; Church N; Satsangi J; Arnott ID;
    Aliment Pharmacol Ther; 2007 Aug; 26(3):411-9. PubMed ID: 17635376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
    Gonzalez-Lama Y; Fernandez-Blanco I; Lopez-SanRoman A; Taxonera C; Casis B; Tabernero S; Bermejo F; Martinez-Silva F; Mendoza JL; Martinez-Montiel P; Carneros JA; Sanchez F; Maté J; Gisbert JP;
    Hepatogastroenterology; 2008; 55(86-87):1609-14. PubMed ID: 19102352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):359-63. PubMed ID: 22187700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy.
    Aloi M; D'Arcangelo G; Capponi M; Nuti F; Vassallo F; Civitelli F; Oliva S; Pagliaro G; Cucchiara S
    Dig Liver Dis; 2015 Jun; 47(6):455-9. PubMed ID: 25733340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis.
    Turner D; Seow CH; Greenberg GR; Griffiths AM; Silverberg MS; Steinhart AH
    Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1081-8. PubMed ID: 19577010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.